FutureWiseResearch: Global Market Research Reports, USA, UK

Overview

Some of the factors that are driving the global resistant depression treatment market include:

Resistant Depression Treatment Market is foreseen to value over CAGR of 3% during the forecast period of 2022-2028.
According to the World Health Organization around 300 million people around the world have depression. At present switching antidepressants, increasing dosages, allowing more time for medications to work, augmented medication for other conditions, neuro-stimulation and psychotherapy are some of the ways for resistant depression treatment. However, burgeoning demand to counter the therapeutic challenge resulted in the emergence of innovative resistant depression treatment. Recently ketamine-based depression treatments are gaining preference as major biopharmaceutical companies receive a green signal from the Food and Drug Administration (FDA).
•
Rise in demand for antidepressant treatment due to increasing mental health issues
•
Burden on the healthcare system due to nonresponding patients to a combination of antidepressants
•
Ageing population as well as increased anxiety and depression syndrome in the millennials
•
Ineffectiveness of antidepressants due to an individual’s genetic composition
•
Exposure to addictive substances that prevent antidepressant medications to positively treat patients
Stigma related to depressive disorder treatments, patent expiration, fear of drug withdrawals, high cost, lack of substantial clinical trials to gauge the efficacy of resistant depression medicines contribute as the major restraints to the global resistant depression treatment market.
High prevalence of depression and mental disorders with substantial treatment resistance in Europe and North America are indicative of progressive growth of the market. Increasing awareness about mental health and related treatments are anticipated to create greater opportunities in the near future amongst the emerging nations in the Asia-Pacific and rest of the world.

Resistant Depression Treatment Key Market Players:

Roche Holding, Johnson
Johnson, MerckCo., Novartis AG, Pfizer Inc., Janssen Pharmaceuticals, Seelos Therapeutics, Bristol-Myers Squibb, GlaxoSmithKline plc and others

Resistant Depression Treatment Market Segmentation :

By Drug Type
•
Selective serotonin reuptake inhibitors
•
Serotonin-norepinephrine reuptake inhibitors
•
Tricyclic antidepressants
•
Monoamine oxidase inhibitors
•
Atypical agents
By Distribution Channel
•
Hospital Pharmacies
•
Retail Pharmacies
•
Mail Order Pharmacies
By Region
•
North America
•
Latin America
•
Europe
•
Asia Pacific
•
Middle East and Africa

Competitive Landscape:

•
Tier 1 players - established companies in the market with a major market share
•
Tier 2 players
•
Emerging players which are growing rapidly
•
New Entrants
FutureWise Key Takeaways
•
Growth prospects
•
SWOT analysis
•
Key trends
•
Key data-points affecting market growth

Objectives of the Study:

•
To provide with an exhaustive analysis on the global resistant depression treatment market on the basis of drug type, distribution channel, and region
•
To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
•
To evaluate and forecast micro-markets and the overall market
•
To predict the market size, in key regions (along with countries)—North America, Europe, Asia Pacific, Latin America, and the
Middle East and Africa
•
To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions
•
Profiling of companies to evaluate their market shares, strategies, financials and core competencies

Flexible Delivery Model:

• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customization Mobility Care offered are free of charge with purchase of any license of the report
• You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

1. Market Introduction
- 1. Objectives of the Study
  2. Market Definition
  3. Market Scope
  3.1. Years Considered for the Study
  3.2. Market Covered
  4. Currency
  5. Limitations
  6. Stakeholders
2. Research Methodology
- 1. Research Data
  1.1. Secondary Data
  1.1.1. Key Data from Secondary Sources
  1.2. Primary Data
  1.2.1. Key Data from Primary Sources
  2. Market Size Estimation
  3. Market Breakdown and Data Triangulation
  4. Assumptions for the Study
3. Executive Summary
- 1. Market Outlook
  2. Segment Outlook
  3. Competitive Insights
4. Global Resistant Depression Treatment Market Variables, Trends
- Scope
  1. Market Lineage Outlook
  2. Penetration and Growth Prospect Mapping
  3. Industry Value Chain Analysis
  4. Cost Analysis Breakdown
  5. Technology Overview
  6. Regulatory Framework
  6.1. Reimbursement Framework
  6.2. Standards and Compliances
5. Global Resistant Depression Treatment Market Overview
- 1. Market Dynamics
  1.1. Market Driver Analysis
  1.1.1. Increasing focus of Resistant Depression Treatment Companies on Brand Protection
  1.1.2. Untapped Opportunities in Emerging Regions
  1.2. Market Restraint Analysis
  1.2.1. High Cost Associated with Implementation of Predictive Analysis
  1.3. Industry Challenges
  1.3.1. Presence of Ambiguous Regulatory Framework
6. Global Resistant Depression Treatment Market Analysis Tools
- 1. Industry Analysis - Porter’s
  1.1. Supplier Power
  1.2. Buyer Power
  1.3. Substitution Threat
  1.4. Threat from New Entrants
  1.5. Competitive Rivalry
  2. Pestel Analysis
  2.1. Political Landscape
  2.2. Environmental Landscape
  2.3. Social Landscape
  2.4. Technology Landscape
  2.5. Legal Landscape
  3. Major Deals And Strategic Alliances Analysis
  3.1. Joint Ventures
  3.2. Mergers and Acquisitions
  3.3. Licensing and Partnership
  3.4. Technology Collaborations
  3.5. Strategic Divestments
  4. Market Entry Strategies
  5. Case Studies
7. Global Resistant Depression Treatment Market, By Drug Type Historical Analysis and Forecast 2022-2027 (USD Million)
- 1. Selective serotonin reuptake inhibitors
  2. Serotonin-norepinephrine reuptake inhibitors
  3. Tricyclic antidepressants
  4. Monoamine oxidase inhibitors
  5. Atypical agents
8. Global Resistant Depression Treatment Market, By Distribution Channel Historical Analysis and Forecast 2022-2027 (USD Million)
- 1. Hospital Pharmacies
  2. Retail Pharmacies
  3. Mail Order Pharmacies
9. North America Market Analysis 2016–2020 and Forecast 2022–2027 (USD Million)
- 1. Introduction
  2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
  2.1. U.S.A
  2.2. Canada
  2.3. Mexico
  3. Market Size (USD Million) Forecast for North America 2022-2027
10. Latin America Market Analysis 2016–2020 and Forecast 2022–2027 (USD Million)
- 1. Introduction
  2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
  2.1. Brazil
  2.2. Venezuela
  2.3. Argentina
  2.4. Rest of Latin America
  3. Market Size (USD Million) Forecast for Latin America 2022-2027
11. Europe Market Analysis 2016–2020 and Forecast 2022–2027 (USD Million)
- 1. Introduction
  2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
  2.1. Germany
  2.2. U.K
  2.3. France
  2.4. Italy
  2.5. Spain
  2.6. Russia
  2.7. Poland
  2.8. Rest of Europe
  3. Market Size (USD Million) Forecast for Europe 2022-2027
12. Asia Pacific Market Analysis 2016–2020 and Forecast 2022–2027 (USD Million)
- 1. Introduction
  2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
  2.1. Japan
  2.2. China
  2.3. India
  2.4. Australia and New Zealand
  2.5. ASEAN
  2.6. Rest of Asia Pacific
  3. Market Size (USD Million) Forecast for Asia Pacific 2022-2027
13. Middle East and Africa Market Analysis 2015–2020 and Forecast 2022–2027 (USD Million)
- 1. Introduction
  2. Historical Market Size (USD Million) Analysis By Country, 2015-2020
  2.1. Saudi Arabia
  2.2. UAE
  2.3. South Africa
  2.4. Egypt
  3. Market Size (USD Million) Forecast for MEA 2022-2027
14. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Connected Devices and Disease Indication Portfolio, Financial Layouts)
- 1. Roche Holding
  1.1. Company Overview
  1.2. Product Portfolio
  1.3. SWOT Analysis
  1.4. Financial Overview
  1.5. Strategic Overview
  2. Johnson
  Johnson
  2.1. Company Overview
  2.2. Product Portfolio
  2.3. SWOT Analysis
  2.4. Financial Overview
  2.5. Strategic Overview
  3. MerckCo.
  3.1. Company Overview
  3.2. Product Portfolio
  3.3. SWOT Analysis
  3.4. Financial Overview
  3.5. Strategic Overview
  4. Novartis AG
  4.1. Company Overview
  4.2. Product Portfolio
  4.3. SWOT Analysis
  4.4. Financial Overview
  4.5. Strategic Overview
  14.5 . Pfizer Inc.
  5.1. Company Overview
  5.2. Product Portfolio
  5.3. SWOT Analysis
  5.4. Financial Overview
  5.5. Strategic Overview
  14.6 . Janssen Pharmaceuticals
  6.1. Company Overview
  6.2. Product Portfolio
  6.3. SWOT Analysis
  6.4. Financial Overview
  6.5. Strategic Overview
  7. Seelos Therapeutics
  7.1. Company Overview
  7.2. Product Portfolio
  7.3. SWOT Analysis
  7.4. Financial Overview
  7.5. Strategic Overview
  8. Bristol-Myers Squibb
  8.1. Company Overview
  8.2. Product Portfolio
  8.3. SWOT Analysis
  8.4. Financial Overview
  8.5. Strategic Overview
  9. GlaxoSmithKline plc
  9.1. Company Overview
  9.2. Product Portfolio
  9.3. SWOT Analysis
  9.4. Financial Overview
  9.5. Strategic Overview
15. Pre and Post COVID-19 Impact
- 1. Positive influence on the healthcare industry
  2. The financial disruption of the manufacturing sector
  3. Impact of COVID-19 on emerging companies
  4. Significant mandates in the healthcare regulations initiated by administrations
  5. The overall economic slowdown of the developing and developed nations
16. FutureWise SME Key Takeaway Points for Client

Data Pack license: Data Pack license: $1250

Single user license: Single user license: $2850

Multi user license: Multi user license: $3850

Corporate license: Corporate license: $5000

Ask for Discount

Buy Now

Customize This Report

Partner

Report Overview

Table of Contents

List of Tables

List of figures

Overview

Table of Contents

Report Overview

Table of Contents

List of Tables

List of figures

Need Assistance

What you get

What's included

Our Clients